http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Thu, 22 Oct 2026 16:28:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Kiniksa+Pharmaceuticals+++For%3A+Oct+17/27223031.html si-local-file:///var/storage/secattach/20261022/27223031.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Kiniksa+Pharmaceuticals+++For%3A+Oct+17/27223031.html Thu, 22 Oct 2026 16:28:00 -0400 KNSA http://www.streetinsider.com/Press+Releases/Kiniksa+Pharmaceuticals+to+Report+Third+Quarter+2026+Financial+Results+on+October+27%2C+2026/27222446.html <p align="left">LONDON, Oct. 22, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=QNDAcPBFwaR1sETMYpPfSXnuNfle4WtVQyn7tz4jT0z9rn4WeS4FhimoLGJgCLUOxcSzYLvednLm-0jeNTKY6OJgf1pt5Dv-_S5v8RrL35GDi79dS_-7CadGD0G43V4i" rel="nofollow" target="_blank">Kiniksa Pharmaceuticals International, plc</a> (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Tuesday, October 27, 2026 at 8:30 a.m. Eastern Time to report its third quarter 2026 financial results and recent portfolio execution.</p> <p>A live webcast will be accessible through the Investors &amp; Media section of the company’s website at <a target="_blank" href="https://www.globenewswire.com/Tracker?data=1ChdCCXWQQlcm1aaLndEWTj-BOrhlbUJDG6aVQNPP-gVNtnXTrak6ZpQrl6KfqJbjKcKxdQSzF92VMLwkd1-4DB2m3WxlhAs4ny7xv_GKeE=" rel="nofollow" target="_blank">www.kiniksa.com</a>. Individuals interested in participating in the call via telephone may register <a target="_blank" href="https://www.globenewswire.com/Tracker?data=QhI1IrXwjM30SCXsX9gxudeHr1NzKFgWJBKa50K_tFHufLWtfa-mGUzQ14h4QtrAVonsGdriQimk-drrkPADgZhXMh0iPDFY6Nvthuvt4Sf506fHTkKsIH1mB5Xf2LklD8SNyxlG3ftpcwPiOTbiwGsgaYaM9OdHN2YOfBjUDT8=" rel="nofollow" target="_blank">here</a>. Upon registration, all telephone participants will receive http://www.streetinsider.com/Press+Releases/Kiniksa+Pharmaceuticals+to+Report+Third+Quarter+2026+Financial+Results+on+October+27%2C+2026/27222446.html Thu, 22 Oct 2026 16:01:00 -0400 KNSA http://www.streetinsider.com/Globe+Newswire/Kiniksa+Pharmaceuticals+to+Report+Third+Quarter+2026+Financial+Results+on+October+27%2C+2026/27222446.html <p align="left">LONDON, Oct. 22, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=QNDAcPBFwaR1sETMYpPfSXnuNfle4WtVQyn7tz4jT0z9rn4WeS4FhimoLGJgCLUOxcSzYLvednLm-0jeNTKY6OJgf1pt5Dv-_S5v8RrL35GDi79dS_-7CadGD0G43V4i" rel="nofollow" target="_blank">Kiniksa Pharmaceuticals International, plc</a> (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Tuesday, October 27, 2026 at 8:30 a.m. Eastern Time to report its third quarter 2026 financial results and recent portfolio execution.</p> <p>A live webcast will be accessible through the Investors &amp; Media section of the company’s website at <a target="_blank" href="https://www.globenewswire.com/Tracker?data=1ChdCCXWQQlcm1aaLndEWTj-BOrhlbUJDG6aVQNPP-gVNtnXTrak6ZpQrl6KfqJbjKcKxdQSzF92VMLwkd1-4DB2m3WxlhAs4ny7xv_GKeE=" rel="nofollow" target="_blank">www.kiniksa.com</a>. Individuals interested in participating in the call via telephone may register <a target="_blank" href="https://www.globenewswire.com/Tracker?data=QhI1IrXwjM30SCXsX9gxudeHr1NzKFgWJBKa50K_tFHufLWtfa-mGUzQ14h4QtrAVonsGdriQimk-drrkPADgZhXMh0iPDFY6Nvthuvt4Sf506fHTkKsIH1mB5Xf2LklD8SNyxlG3ftpcwPiOTbiwGsgaYaM9OdHN2YOfBjUDT8=" rel="nofollow" target="_blank">here</a>. Upon registration, all telephone participants will receive http://www.streetinsider.com/Globe+Newswire/Kiniksa+Pharmaceuticals+to+Report+Third+Quarter+2026+Financial+Results+on+October+27%2C+2026/27222446.html Thu, 22 Oct 2026 16:01:00 -0400 KNSA http://www.streetinsider.com/Hot+List/U.S.+biotech+SMids%3A+Q3+earnings+preview/27199432.html <p>Citi is out with its preview into Q3 earnings of U.S. Smid biotech stocks, noting that a continued catalyst calendar and business development engagement have kept investor interest high in this part of the market. The firm has shared with investors key catalysts to watch.</p><p>While conversations on large-cap Biopharma tend to have policy and AI in focus, SMids “offer a more direct investment case around clinical data, regulatory progress, and launch execution.”</p><p>Also, while high interest rates are a valuation and financing headwind, the market sees the situation as temporary, which according to Citi, will allow IPO momentum to continue.</p><p>Given this http://www.streetinsider.com/Hot+List/U.S.+biotech+SMids%3A+Q3+earnings+preview/27199432.html Sun, 18 Oct 2026 20:00:00 -0400 ABOS AMLX BNTX FTH JAZZ KNSA KYMR MANE MRNA NAMS NUVB NVAX PTGX SRRK VOR http://www.streetinsider.com/Hot+List+Pro/U.S.+biotech+SMids%3A+Q3+earnings+preview/27199432.html <p>Citi is out with its preview into Q3 earnings of U.S. Smid biotech stocks, noting that a continued catalyst calendar and business development engagement have kept investor interest high in this part of the market. The firm has shared with investors key catalysts to watch.</p><p>While conversations on large-cap Biopharma tend to have policy and AI in focus, SMids “offer a more direct investment case around clinical data, regulatory progress, and launch execution.”</p><p>Also, while high interest rates are a valuation and financing headwind, the market sees the situation as temporary, which according to Citi, will allow IPO momentum to continue.</p><p>Given this http://www.streetinsider.com/Hot+List+Pro/U.S.+biotech+SMids%3A+Q3+earnings+preview/27199432.html Sun, 18 Oct 2026 20:00:00 -0400 ABOS AMLX BNTX FTH JAZZ KNSA KYMR MANE MRNA NAMS NUVB NVAX PTGX SRRK VOR http://www.streetinsider.com/Hot+List/U.S.+biotech+SMids%3A+Q3+earnings+preview/27199432.html <p>Citi is out with its preview into Q3 earnings of U.S. Smid biotech stocks, noting that a continued catalyst calendar and business development engagement have kept investor interest high in this part of the market. The firm has shared with investors key catalysts to watch.</p><p>While conversations on large-cap Biopharma tend to have policy and AI in focus, SMids “offer a more direct investment case around clinical data, regulatory progress, and launch execution.”</p><p>Also, while high interest rates are a valuation and financing headwind, the market sees the situation as temporary, which according to Citi, will allow IPO momentum to continue.</p><p>Given this http://www.streetinsider.com/Hot+List/U.S.+biotech+SMids%3A+Q3+earnings+preview/27199432.html Sun, 18 Oct 2026 20:00:00 -0400 ABOS AMLX BNTX FTH JAZZ KNSA KYMR MANE MRNA NAMS NUVB NVAX PTGX SRRK VOR http://www.streetinsider.com/Hot+List+Pro/U.S.+biotech+SMids%3A+Q3+earnings+preview/27199432.html <p>Citi is out with its preview into Q3 earnings of U.S. Smid biotech stocks, noting that a continued catalyst calendar and business development engagement have kept investor interest high in this part of the market. The firm has shared with investors key catalysts to watch.</p><p>While conversations on large-cap Biopharma tend to have policy and AI in focus, SMids “offer a more direct investment case around clinical data, regulatory progress, and launch execution.”</p><p>Also, while high interest rates are a valuation and financing headwind, the market sees the situation as temporary, which according to Citi, will allow IPO momentum to continue.</p><p>Given this http://www.streetinsider.com/Hot+List+Pro/U.S.+biotech+SMids%3A+Q3+earnings+preview/27199432.html Sun, 18 Oct 2026 20:00:00 -0400 ABOS AMLX BNTX FTH JAZZ KNSA KYMR MANE MRNA NAMS NUVB NVAX PTGX SRRK VOR http://www.streetinsider.com/Hot+List/U.S.+biotech+SMids%3A+Q3+earnings+preview/27199432.html <p>Citi is out with its preview into Q3 earnings of U.S. Smid biotech stocks, noting that a continued catalyst calendar and business development engagement have kept investor interest high in this part of the market. The firm has shared with investors key catalysts to watch.</p><p>While conversations on large-cap Biopharma tend to have policy and AI in focus, SMids “offer a more direct investment case around clinical data, regulatory progress, and launch execution.”</p><p>Also, while high interest rates are a valuation and financing headwind, the market sees the situation as temporary, which according to Citi, will allow IPO momentum to continue.</p><p>Given this http://www.streetinsider.com/Hot+List/U.S.+biotech+SMids%3A+Q3+earnings+preview/27199432.html Sun, 18 Oct 2026 20:00:00 -0400 ABOS AMLX BNTX FTH JAZZ KNSA KYMR MANE MRNA NAMS NUVB NVAX PTGX SRRK VOR http://www.streetinsider.com/Hot+List+Pro/U.S.+biotech+SMids%3A+Q3+earnings+preview/27199432.html <p>Citi is out with its preview into Q3 earnings of U.S. Smid biotech stocks, noting that a continued catalyst calendar and business development engagement have kept investor interest high in this part of the market. The firm has shared with investors key catalysts to watch.</p><p>While conversations on large-cap Biopharma tend to have policy and AI in focus, SMids “offer a more direct investment case around clinical data, regulatory progress, and launch execution.”</p><p>Also, while high interest rates are a valuation and financing headwind, the market sees the situation as temporary, which according to Citi, will allow IPO momentum to continue.</p><p>Given this http://www.streetinsider.com/Hot+List+Pro/U.S.+biotech+SMids%3A+Q3+earnings+preview/27199432.html Sun, 18 Oct 2026 20:00:00 -0400 ABOS AMLX BNTX FTH JAZZ KNSA KYMR MANE MRNA NAMS NUVB NVAX PTGX SRRK VOR http://www.streetinsider.com/Hot+List/U.S.+biotech+SMids%3A+Q3+earnings+preview/27199432.html <p>Citi is out with its preview into Q3 earnings of U.S. Smid biotech stocks, noting that a continued catalyst calendar and business development engagement have kept investor interest high in this part of the market. The firm has shared with investors key catalysts to watch.</p><p>While conversations on large-cap Biopharma tend to have policy and AI in focus, SMids “offer a more direct investment case around clinical data, regulatory progress, and launch execution.”</p><p>Also, while high interest rates are a valuation and financing headwind, the market sees the situation as temporary, which according to Citi, will allow IPO momentum to continue.</p><p>Given this http://www.streetinsider.com/Hot+List/U.S.+biotech+SMids%3A+Q3+earnings+preview/27199432.html Sun, 18 Oct 2026 20:00:00 -0400 ABOS AMLX BNTX FTH JAZZ KNSA KYMR MANE MRNA NAMS NUVB NVAX PTGX SRRK VOR http://www.streetinsider.com/Hot+List+Pro/U.S.+biotech+SMids%3A+Q3+earnings+preview/27199432.html <p>Citi is out with its preview into Q3 earnings of U.S. Smid biotech stocks, noting that a continued catalyst calendar and business development engagement have kept investor interest high in this part of the market. The firm has shared with investors key catalysts to watch.</p><p>While conversations on large-cap Biopharma tend to have policy and AI in focus, SMids “offer a more direct investment case around clinical data, regulatory progress, and launch execution.”</p><p>Also, while high interest rates are a valuation and financing headwind, the market sees the situation as temporary, which according to Citi, will allow IPO momentum to continue.</p><p>Given this http://www.streetinsider.com/Hot+List+Pro/U.S.+biotech+SMids%3A+Q3+earnings+preview/27199432.html Sun, 18 Oct 2026 20:00:00 -0400 ABOS AMLX BNTX FTH JAZZ KNSA KYMR MANE MRNA NAMS NUVB NVAX PTGX SRRK VOR http://www.streetinsider.com/Hot+List/U.S.+biotech+SMids%3A+Q3+earnings+preview/27199432.html <p>Citi is out with its preview into Q3 earnings of U.S. Smid biotech stocks, noting that a continued catalyst calendar and business development engagement have kept investor interest high in this part of the market. The firm has shared with investors key catalysts to watch.</p><p>While conversations on large-cap Biopharma tend to have policy and AI in focus, SMids “offer a more direct investment case around clinical data, regulatory progress, and launch execution.”</p><p>Also, while high interest rates are a valuation and financing headwind, the market sees the situation as temporary, which according to Citi, will allow IPO momentum to continue.</p><p>Given this http://www.streetinsider.com/Hot+List/U.S.+biotech+SMids%3A+Q3+earnings+preview/27199432.html Sun, 18 Oct 2026 20:00:00 -0400 ABOS AMLX BNTX FTH JAZZ KNSA KYMR MANE MRNA NAMS NUVB NVAX PTGX SRRK VOR http://www.streetinsider.com/Hot+List+Pro/U.S.+biotech+SMids%3A+Q3+earnings+preview/27199432.html <p>Citi is out with its preview into Q3 earnings of U.S. Smid biotech stocks, noting that a continued catalyst calendar and business development engagement have kept investor interest high in this part of the market. The firm has shared with investors key catalysts to watch.</p><p>While conversations on large-cap Biopharma tend to have policy and AI in focus, SMids “offer a more direct investment case around clinical data, regulatory progress, and launch execution.”</p><p>Also, while high interest rates are a valuation and financing headwind, the market sees the situation as temporary, which according to Citi, will allow IPO momentum to continue.</p><p>Given this http://www.streetinsider.com/Hot+List+Pro/U.S.+biotech+SMids%3A+Q3+earnings+preview/27199432.html Sun, 18 Oct 2026 20:00:00 -0400 ABOS AMLX BNTX FTH JAZZ KNSA KYMR MANE MRNA NAMS NUVB NVAX PTGX SRRK VOR http://www.streetinsider.com/Hot+List/U.S.+biotech+SMids%3A+Q3+earnings+preview/27199432.html <p>Citi is out with its preview into Q3 earnings of U.S. Smid biotech stocks, noting that a continued catalyst calendar and business development engagement have kept investor interest high in this part of the market. The firm has shared with investors key catalysts to watch.</p><p>While conversations on large-cap Biopharma tend to have policy and AI in focus, SMids “offer a more direct investment case around clinical data, regulatory progress, and launch execution.”</p><p>Also, while high interest rates are a valuation and financing headwind, the market sees the situation as temporary, which according to Citi, will allow IPO momentum to continue.</p><p>Given this http://www.streetinsider.com/Hot+List/U.S.+biotech+SMids%3A+Q3+earnings+preview/27199432.html Sun, 18 Oct 2026 20:00:00 -0400 ABOS AMLX BNTX FTH JAZZ KNSA KYMR MANE MRNA NAMS NUVB NVAX PTGX SRRK VOR http://www.streetinsider.com/Hot+List+Pro/U.S.+biotech+SMids%3A+Q3+earnings+preview/27199432.html <p>Citi is out with its preview into Q3 earnings of U.S. Smid biotech stocks, noting that a continued catalyst calendar and business development engagement have kept investor interest high in this part of the market. The firm has shared with investors key catalysts to watch.</p><p>While conversations on large-cap Biopharma tend to have policy and AI in focus, SMids “offer a more direct investment case around clinical data, regulatory progress, and launch execution.”</p><p>Also, while high interest rates are a valuation and financing headwind, the market sees the situation as temporary, which according to Citi, will allow IPO momentum to continue.</p><p>Given this http://www.streetinsider.com/Hot+List+Pro/U.S.+biotech+SMids%3A+Q3+earnings+preview/27199432.html Sun, 18 Oct 2026 20:00:00 -0400 ABOS AMLX BNTX FTH JAZZ KNSA KYMR MANE MRNA NAMS NUVB NVAX PTGX SRRK VOR http://www.streetinsider.com/Hot+List/U.S.+biotech+SMids%3A+Q3+earnings+preview/27199432.html <p>Citi is out with its preview into Q3 earnings of U.S. Smid biotech stocks, noting that a continued catalyst calendar and business development engagement have kept investor interest high in this part of the market. The firm has shared with investors key catalysts to watch.</p><p>While conversations on large-cap Biopharma tend to have policy and AI in focus, SMids “offer a more direct investment case around clinical data, regulatory progress, and launch execution.”</p><p>Also, while high interest rates are a valuation and financing headwind, the market sees the situation as temporary, which according to Citi, will allow IPO momentum to continue.</p><p>Given this http://www.streetinsider.com/Hot+List/U.S.+biotech+SMids%3A+Q3+earnings+preview/27199432.html Sun, 18 Oct 2026 20:00:00 -0400 ABOS AMLX BNTX FTH JAZZ KNSA KYMR MANE MRNA NAMS NUVB NVAX PTGX SRRK VOR http://www.streetinsider.com/Hot+List+Pro/U.S.+biotech+SMids%3A+Q3+earnings+preview/27199432.html <p>Citi is out with its preview into Q3 earnings of U.S. Smid biotech stocks, noting that a continued catalyst calendar and business development engagement have kept investor interest high in this part of the market. The firm has shared with investors key catalysts to watch.</p><p>While conversations on large-cap Biopharma tend to have policy and AI in focus, SMids “offer a more direct investment case around clinical data, regulatory progress, and launch execution.”</p><p>Also, while high interest rates are a valuation and financing headwind, the market sees the situation as temporary, which according to Citi, will allow IPO momentum to continue.</p><p>Given this http://www.streetinsider.com/Hot+List+Pro/U.S.+biotech+SMids%3A+Q3+earnings+preview/27199432.html Sun, 18 Oct 2026 20:00:00 -0400 ABOS AMLX BNTX FTH JAZZ KNSA KYMR MANE MRNA NAMS NUVB NVAX PTGX SRRK VOR http://www.streetinsider.com/Hot+List/U.S.+biotech+SMids%3A+Q3+earnings+preview/27199432.html <p>Citi is out with its preview into Q3 earnings of U.S. Smid biotech stocks, noting that a continued catalyst calendar and business development engagement have kept investor interest high in this part of the market. The firm has shared with investors key catalysts to watch.</p><p>While conversations on large-cap Biopharma tend to have policy and AI in focus, SMids “offer a more direct investment case around clinical data, regulatory progress, and launch execution.”</p><p>Also, while high interest rates are a valuation and financing headwind, the market sees the situation as temporary, which according to Citi, will allow IPO momentum to continue.</p><p>Given this http://www.streetinsider.com/Hot+List/U.S.+biotech+SMids%3A+Q3+earnings+preview/27199432.html Sun, 18 Oct 2026 20:00:00 -0400 ABOS AMLX BNTX FTH JAZZ KNSA KYMR MANE MRNA NAMS NUVB NVAX PTGX SRRK VOR http://www.streetinsider.com/Hot+List+Pro/U.S.+biotech+SMids%3A+Q3+earnings+preview/27199432.html <p>Citi is out with its preview into Q3 earnings of U.S. Smid biotech stocks, noting that a continued catalyst calendar and business development engagement have kept investor interest high in this part of the market. The firm has shared with investors key catalysts to watch.</p><p>While conversations on large-cap Biopharma tend to have policy and AI in focus, SMids “offer a more direct investment case around clinical data, regulatory progress, and launch execution.”</p><p>Also, while high interest rates are a valuation and financing headwind, the market sees the situation as temporary, which according to Citi, will allow IPO momentum to continue.</p><p>Given this http://www.streetinsider.com/Hot+List+Pro/U.S.+biotech+SMids%3A+Q3+earnings+preview/27199432.html Sun, 18 Oct 2026 20:00:00 -0400 ABOS AMLX BNTX FTH JAZZ KNSA KYMR MANE MRNA NAMS NUVB NVAX PTGX SRRK VOR http://www.streetinsider.com/Hot+List/U.S.+biotech+SMids%3A+Q3+earnings+preview/27199432.html <p>Citi is out with its preview into Q3 earnings of U.S. Smid biotech stocks, noting that a continued catalyst calendar and business development engagement have kept investor interest high in this part of the market. The firm has shared with investors key catalysts to watch.</p><p>While conversations on large-cap Biopharma tend to have policy and AI in focus, SMids “offer a more direct investment case around clinical data, regulatory progress, and launch execution.”</p><p>Also, while high interest rates are a valuation and financing headwind, the market sees the situation as temporary, which according to Citi, will allow IPO momentum to continue.</p><p>Given this http://www.streetinsider.com/Hot+List/U.S.+biotech+SMids%3A+Q3+earnings+preview/27199432.html Sun, 18 Oct 2026 20:00:00 -0400 ABOS AMLX BNTX FTH JAZZ KNSA KYMR MANE MRNA NAMS NUVB NVAX PTGX SRRK VOR http://www.streetinsider.com/Hot+List+Pro/U.S.+biotech+SMids%3A+Q3+earnings+preview/27199432.html <p>Citi is out with its preview into Q3 earnings of U.S. Smid biotech stocks, noting that a continued catalyst calendar and business development engagement have kept investor interest high in this part of the market. The firm has shared with investors key catalysts to watch.</p><p>While conversations on large-cap Biopharma tend to have policy and AI in focus, SMids “offer a more direct investment case around clinical data, regulatory progress, and launch execution.”</p><p>Also, while high interest rates are a valuation and financing headwind, the market sees the situation as temporary, which according to Citi, will allow IPO momentum to continue.</p><p>Given this http://www.streetinsider.com/Hot+List+Pro/U.S.+biotech+SMids%3A+Q3+earnings+preview/27199432.html Sun, 18 Oct 2026 20:00:00 -0400 ABOS AMLX BNTX FTH JAZZ KNSA KYMR MANE MRNA NAMS NUVB NVAX PTGX SRRK VOR http://www.streetinsider.com/Hot+List/U.S.+biotech+SMids%3A+Q3+earnings+preview/27199432.html <p>Citi is out with its preview into Q3 earnings of U.S. Smid biotech stocks, noting that a continued catalyst calendar and business development engagement have kept investor interest high in this part of the market. The firm has shared with investors key catalysts to watch.</p><p>While conversations on large-cap Biopharma tend to have policy and AI in focus, SMids “offer a more direct investment case around clinical data, regulatory progress, and launch execution.”</p><p>Also, while high interest rates are a valuation and financing headwind, the market sees the situation as temporary, which according to Citi, will allow IPO momentum to continue.</p><p>Given this http://www.streetinsider.com/Hot+List/U.S.+biotech+SMids%3A+Q3+earnings+preview/27199432.html Sun, 18 Oct 2026 20:00:00 -0400 ABOS AMLX BNTX FTH JAZZ KNSA KYMR MANE MRNA NAMS NUVB NVAX PTGX SRRK VOR http://www.streetinsider.com/Hot+List+Pro/U.S.+biotech+SMids%3A+Q3+earnings+preview/27199432.html <p>Citi is out with its preview into Q3 earnings of U.S. Smid biotech stocks, noting that a continued catalyst calendar and business development engagement have kept investor interest high in this part of the market. The firm has shared with investors key catalysts to watch.</p><p>While conversations on large-cap Biopharma tend to have policy and AI in focus, SMids “offer a more direct investment case around clinical data, regulatory progress, and launch execution.”</p><p>Also, while high interest rates are a valuation and financing headwind, the market sees the situation as temporary, which according to Citi, will allow IPO momentum to continue.</p><p>Given this http://www.streetinsider.com/Hot+List+Pro/U.S.+biotech+SMids%3A+Q3+earnings+preview/27199432.html Sun, 18 Oct 2026 20:00:00 -0400 ABOS AMLX BNTX FTH JAZZ KNSA KYMR MANE MRNA NAMS NUVB NVAX PTGX SRRK VOR http://www.streetinsider.com/Hot+List/U.S.+biotech+SMids%3A+Q3+earnings+preview/27199432.html <p>Citi is out with its preview into Q3 earnings of U.S. Smid biotech stocks, noting that a continued catalyst calendar and business development engagement have kept investor interest high in this part of the market. The firm has shared with investors key catalysts to watch.</p><p>While conversations on large-cap Biopharma tend to have policy and AI in focus, SMids “offer a more direct investment case around clinical data, regulatory progress, and launch execution.”</p><p>Also, while high interest rates are a valuation and financing headwind, the market sees the situation as temporary, which according to Citi, will allow IPO momentum to continue.</p><p>Given this http://www.streetinsider.com/Hot+List/U.S.+biotech+SMids%3A+Q3+earnings+preview/27199432.html Sun, 18 Oct 2026 20:00:00 -0400 ABOS AMLX BNTX FTH JAZZ KNSA KYMR MANE MRNA NAMS NUVB NVAX PTGX SRRK VOR http://www.streetinsider.com/Hot+List+Pro/U.S.+biotech+SMids%3A+Q3+earnings+preview/27199432.html <p>Citi is out with its preview into Q3 earnings of U.S. Smid biotech stocks, noting that a continued catalyst calendar and business development engagement have kept investor interest high in this part of the market. The firm has shared with investors key catalysts to watch.</p><p>While conversations on large-cap Biopharma tend to have policy and AI in focus, SMids “offer a more direct investment case around clinical data, regulatory progress, and launch execution.”</p><p>Also, while high interest rates are a valuation and financing headwind, the market sees the situation as temporary, which according to Citi, will allow IPO momentum to continue.</p><p>Given this http://www.streetinsider.com/Hot+List+Pro/U.S.+biotech+SMids%3A+Q3+earnings+preview/27199432.html Sun, 18 Oct 2026 20:00:00 -0400 ABOS AMLX BNTX FTH JAZZ KNSA KYMR MANE MRNA NAMS NUVB NVAX PTGX SRRK VOR